STOCK TITAN

Zenas BioPharma Inc. - ZBIO STOCK NEWS

Welcome to our dedicated page for Zenas BioPharma news (Ticker: ZBIO), a resource for investors and traders seeking the latest updates and insights on Zenas BioPharma stock.

Zenas BioPharma Inc (ZBIO) is a clinical-stage biopharmaceutical company advancing innovative therapies for autoimmune diseases through its lead candidate obexelimab. This page serves as the definitive source for verified company news and developments.

Access timely updates on clinical trial progress, regulatory milestones, and strategic partnerships. Our curated collection includes press releases detailing phase advancements, research collaborations, and scientific presentations – all essential for tracking ZBIO's novel approach to B-cell modulation therapies.

Key focus areas include updates on obexelimab's development, a bifunctional antibody targeting CD19/FcγRIIb receptors designed to modulate immune responses without complete B-cell depletion. Stay informed about this potential breakthrough in autoimmune treatment through primary-source documentation.

Bookmark this page for direct access to Zenas BioPharma's official communications, ensuring you maintain current awareness of their progress in developing targeted immunology therapies. Check regularly for new developments in this dynamic clinical-stage biopharma segment.

Rhea-AI Summary

Zenas BioPharma (Nasdaq: ZBIO) has announced key inducement grants for two newly appointed executives. The company's Compensation Committee approved non-qualified stock options on April 15, 2025, as part of their employment agreements.

Dr. Lisa von Moltke, appointed as Head of Research and Development and Chief Medical Officer, received options to purchase 400,000 shares. Dr. Haley Laken, the new Chief Scientific Officer, received options for 250,000 shares.

Both grants have a ten-year term with an exercise price of $8.72 per share, matching Zenas' closing stock price on the grant date. The options will vest over four years, with 25% vesting after one year of employment and the remainder vesting in 36 monthly installments, contingent on continued service.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.3%
Tags
none
-
Rhea-AI Summary

Zenas BioPharma (Nasdaq: ZBIO) has appointed Haley Laken, Ph.D. as Chief Scientific Officer, bringing over 25 years of leadership experience in research and development. Dr. Laken will support the advancement of obexelimab, the company's B cell targeted therapy, through Phase 2 and Phase 3 clinical trials for treating IgG4-related disease, multiple sclerosis, and systemic lupus erythematosus.

Prior to joining Zenas, Dr. Laken served as Chief Operating Officer at Tabby Therapeutics, leading scientific initiatives and company operations. Her experience includes roles as Chief Development Officer at Jounce Therapeutics, senior program leadership at TESARO, and strategic positions at Rhythm Pharmaceuticals, Pfizer, and Wyeth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.52%
Tags
management
-
Rhea-AI Summary

Zenas BioPharma (Nasdaq: ZBIO) has appointed Lisa von Moltke, M.D. as Head of Research and Development and Chief Medical Officer. Dr. von Moltke brings over 30 years of drug development experience across multiple therapeutic areas.

The appointment comes as Zenas advances obexelimab through Phase 2 and Phase 3 clinical trials for autoimmune diseases, including IgG4-related disease, multiple sclerosis, and systemic lupus erythematosus. The drug's unique ability to inhibit B cells without depleting them, combined with its self-administered subcutaneous injection regimen, presents a promising treatment option.

Dr. von Moltke previously served as CMO at Seres Therapeutics and held senior positions at Alkermes, Sanofi/Genzyme, and Millennium. She completed a fellowship in clinical pharmacology at Tufts University and has served as President of the American College of Clinical Pharmacology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.18%
Tags
management
Rhea-AI Summary

Zenas BioPharma (Nasdaq: ZBIO) announced its 2024 achievements and 2025 objectives, highlighting progress in clinical trials for obexelimab, their key autoimmune disease therapy. The company enters 2025 with approximately $350 million in cash, expected to fund operations into Q4 2026.

Key 2024 accomplishments include completing enrollment for the Phase 3 INDIGO trial for IgG4-Related Disease, initiating Phase 2 trials for Multiple Sclerosis (MoonStone) and Systemic Lupus Erythematosus (SunStone), and raising $458.7 million through Series C and IPO funding. The company also out-licensed its thyroid eye disease programs to Zai Lab for Greater China.

For 2025, Zenas anticipates reporting topline results from the MoonStone trial in Q3 2025, Phase 3 INDIGO trial results by year-end 2025, and completing enrollment for the SunStone trial with results expected in H1 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.39%
Tags
none
-
Rhea-AI Summary

Zenas BioPharma (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company focused on immunology-based therapies, has announced its participation in the Guggenheim SMID Cap Biotech Conference. The company's management will engage in a fireside chat presentation scheduled for Wednesday, February 5, 2025, at 3:00 p.m. ET.

Interested parties can access both the live webcast and archived replay of the presentation through the 'Events and Presentations' section within the Investor & Media Relations area of the Zenas BioPharma website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.1%
Tags
conferences
-
Rhea-AI Summary

Zenas BioPharma (ZBIO) completed its IPO, raising $258.7 million in gross proceeds, and reported Q3 2024 financial results. The company completed targeted enrollment for its Phase 3 INDIGO trial of obexelimab for IgG4-RD treatment, with topline results expected by end of 2025. R&D expenses increased to $33.5 million from $9.4 million year-over-year, while G&A expenses rose to $7.5 million from $5.0 million. The company reported a net loss of $38.6 million. Cash balance stands at $386.8 million, expected to fund operations into Q4 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.1%
Tags
Rhea-AI Summary

Zenas BioPharma (NASDAQ: ZBIO) has completed targeted enrollment for its Phase 3 INDIGO trial of obexelimab, a treatment for IgG4-Related Disease (IgG4-RD). The INDIGO trial represents the largest clinical trial ever conducted for IgG4-RD patients. The company expects to report topline results by the end of 2025. This milestone demonstrates Zenas's ability to execute its clinical development plans as it works toward becoming a leader in immunology-based therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.1%
Tags
-
Rhea-AI Summary

Zenas BioPharma (Nasdaq: ZBIO), a clinical-stage biopharmaceutical company, has announced its participation in four major healthcare investor conferences in November and December 2024. The company will present at the Guggenheim's Inaugural Healthcare Innovation Conference in Boston, Jefferies London Healthcare Conference, Citi's Global Healthcare Conference in Miami, and Evercore ISI HealthCONx Conference in Coral Gables. Live webcasts and archived replays of presentations at Jefferies, Citi, and Evercore conferences will be available on the company's website under the Investors and Media section.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.62%
Tags
conferences
-
Rhea-AI Summary

Zenas BioPharma (Nasdaq: ZBIO), a clinical-stage biopharmaceutical company, announced the closing of the underwriters' full exercise of their option to purchase an additional 1,985,294 shares at $17.00 per share in its upsized initial public offering (IPO). This follows the initial offering of 13,235,294 shares, which closed on September 16, 2024. The total offering now amounts to 15,220,588 shares, generating gross proceeds of approximately $258.7 million. The shares began trading on the Nasdaq Global Select Market on September 13, 2024. Morgan Stanley, Jefferies, Citigroup, and Guggenheim Securities served as joint book-running managers. Registration statements for the shares were filed with the U.S. Securities and Exchange Commission and became effective on September 12, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.45%
Tags
Rhea-AI Summary

Zenas BioPharma (Nasdaq: ZBIO) has announced the pricing of its upsized initial public offering (IPO) of 13,235,294 shares at $17.00 per share. The company expects to raise approximately $225.0 million in gross proceeds. Trading on the Nasdaq Global Select Market is set to begin on September 13, 2024, with the offering closing on September 16, 2024. Zenas has granted underwriters a 30-day option to purchase up to an additional 1,985,294 shares at the IPO price. Morgan Stanley, Jefferies, Citigroup, and Guggenheim Securities are acting as joint book-running managers for the offering.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
81.13%
Tags
Zenas BioPharma Inc.

Nasdaq:ZBIO

ZBIO Rankings

ZBIO Stock Data

348.19M
30.66M
24.78%
72.88%
8.17%
Biotechnology
Pharmaceutical Preparations
Link
United States
WALTHAM